Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection.

Gallez-Hawkins GM, Franck AE, Li X, Thao L, Oki A, Gendzekhadze K, Dagis A, Palmer J, Nakamura R, Forman SJ, Senitzer D, Zaia JA.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1662-72. doi: 10.1016/j.bbmt.2011.04.008. Epub 2011 Apr 29.

2.

The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation.

Zaia JA, Sun JY, Gallez-Hawkins GM, Thao L, Oki A, Lacey SF, Dagis A, Palmer J, Diamond DJ, Forman SJ, Senitzer D.

Biol Blood Marrow Transplant. 2009 Mar;15(3):315-25. doi: 10.1016/j.bbmt.2008.11.030.

3.

Cytomegalovirus reactivation after matched sibling donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplant correlates with donor killer immunoglobulin-like receptor genotype.

Sobecks RM, Askar M, Thomas D, Rybicki L, Kalaycio M, Dean R, Avery R, Mossad S, Copelan E, Bolwell BJ.

Exp Clin Transplant. 2011 Feb;9(1):7-13.

4.

Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders.

Chen C, Busson M, Rocha V, Appert ML, Lepage V, Dulphy N, Haas P, Socié G, Toubert A, Charron D, Loiseau P.

Bone Marrow Transplant. 2006 Sep;38(6):437-44. Epub 2006 Aug 7.

PMID:
16892071
5.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched Transplantation in Patients with Donors with KIR Gene Haplotype A.

Wu X, Yao Y, Bao X, Zhou H, Tang X, Han Y, Ma X, Liu Y, Chen J, Zhou H, Jing S, Gu B, Xu Y, Sun A, He J, Wu D.

Biol Blood Marrow Transplant. 2016 Feb;22(2):220-225. doi: 10.1016/j.bbmt.2015.10.004. Epub 2015 Oct 22.

6.

Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation.

Horowitz A, Guethlein LA, Nemat-Gorgani N, Norman PJ, Cooley S, Miller JS, Parham P.

J Immunol. 2015 Nov 1;195(9):4524-36. doi: 10.4049/jimmunol.1401990. Epub 2015 Sep 28.

7.

Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.

George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.

Transpl Infect Dis. 2010 Aug 1;12(4):322-9. doi: 10.1111/j.1399-3062.2010.00504.x. Epub 2010 May 11.

PMID:
20487414
8.

Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation.

Davis ZB, Cooley SA, Cichocki F, Felices M, Wangen R, Luo X, DeFor TE, Bryceson YT, Diamond DJ, Brunstein C, Blazar BR, Wagner JE, Weisdorf DJ, Horowitz A, Guethlein LA, Parham P, Verneris MR, Miller JS.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1653-62. doi: 10.1016/j.bbmt.2015.05.025. Epub 2015 Jun 6.

9.

The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients.

Stern M, Elsässer H, Hönger G, Steiger J, Schaub S, Hess C.

Am J Transplant. 2008 Jun;8(6):1312-7. doi: 10.1111/j.1600-6143.2008.02242.x. Epub 2008 Apr 29.

10.

Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation.

Giebel S, Nowak I, Wojnar J, Markiewicz M, Dziaczkowska J, Wylezol I, Krawczyk-Kulis M, Bloch R, Kusnierczyk P, Holowiecki J.

Transplant Proc. 2006 Jan-Feb;38(1):287-91.

PMID:
16504727
11.

Killer-cell immunoglobulin-like receptors and cytomegalovirus reactivation during late pregnancy.

Alvarado-Hernández DL, Benítez-Sánchez A, Rodríguez-Cuevas JS, Rosales-Saavedra T, Guerra-Palomares SE, Comas-García A, Noyola DE, García-Sepúlveda CA.

Int J Immunogenet. 2016 Aug;43(4):189-99. doi: 10.1111/iji.12271. Epub 2016 Jun 9.

PMID:
27277336
12.

KIR2DS2 and KIR2DS4 promoter hypomethylation patterns in patients undergoing hematopoietic cell transplantation (HCT).

Gallez-Hawkins GM, Li X, Franck AE, Gendzekhadze K, Nakamura R, Forman SJ, Senitzer D, Zaia JA.

Hum Immunol. 2012 Nov;73(11):1109-15. doi: 10.1016/j.humimm.2012.08.013. Epub 2012 Aug 30.

13.

Synergistic effect of KIR ligands missing and cytomegalovirus reactivation in improving outcomes of haematopoietic stem cell transplantation from HLA-matched sibling donor for treatment of myeloid malignancies.

Cardozo DM, Marangon AV, da Silva RF, Aranha FJP, Visentainer JEL, Bonon SHA, Costa SCB, Miranda ECM, de Souza CA, Guimarães F.

Hum Immunol. 2016 Oct;77(10):861-868. doi: 10.1016/j.humimm.2016.07.003. Epub 2016 Jul 6.

PMID:
27394130
14.

[The association of killer cell immunoglobulin like receptor gene polymorphism with cytomegalovirus infection after hematopoietic stem cell transplantation].

Wu XJ, He J, Wu DP, Bao XJ, Xu C, Zhou HF, Sun AN, Han Y, Tang XW, Fu ZZ, Ma X.

Zhonghua Nei Ke Za Zhi. 2013 Feb;52(2):161-5. Chinese.

PMID:
23967614
15.

[Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].

Liang ZY, Ren HY, Cen XN, Qiu ZX, Wang LH, Ou JP, Li Y, Wang MJ, Wang WS, Xu WL, Dong YJ, Yin Y, Sun YH.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Feb;21(1):155-60. doi: 10.7534/j.issn.1009-2137.2013.01.032. Chinese.

PMID:
23484711
16.

Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation.

Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C, Darbyshire P, Lawson S, Boxall E, Moss P.

Blood. 2006 Feb 1;107(3):1230-2. Epub 2005 Oct 20.

17.

KIR and HLA interactions are associated with control of primary CMV infection in solid organ transplant recipients.

van Duin D, Avery RK, Hemachandra S, Yen-Lieberman B, Zhang A, Jain A, Butler RS, Barnard J, Schold JD, Fung J, Askar M.

Am J Transplant. 2014 Jan;14(1):156-62. doi: 10.1111/ajt.12532.

PMID:
24369024
18.

Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation.

Zhao XY, Luo XY, Yu XX, Zhao XS, Han TT, Chang YJ, Huo MR, Xu LP, Zhang XH, Liu KY, Li D, Jiang ZF, Huang XJ.

Br J Haematol. 2017 Jun;177(5):766-781. doi: 10.1111/bjh.14622. Epub 2017 May 3.

PMID:
28466469
19.

[Relationship between CMV reactivation and KIR haplotype/HLA-Cw genotype in patients after unrelated-donor hematopoietic stem cell transplantation.].

Wu XJ, He J, Wu DP, Sun AN, Bao XJ, Qiu QC, Yuan XN, Li WY, Chang HR, Han Y, Ma X, Zhu ZL, Xu Y, Feng YF, Dai LJ.

Zhonghua Xue Ye Xue Za Zhi. 2009 Nov;30(11):741-4. Chinese.

PMID:
20137308
20.

Supplemental Content

Support Center